within Pharmacolibrary.Drugs.ATC.N;

model N02BF03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.872,
    Cl             = 0.00011833333333333333,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.036899999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02BF03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mirogabalin is an oral gabapentinoid derivative developed for the treatment of neuropathic pain, including diabetic peripheral neuropathic pain and postherpetic neuralgia. It is a selective ligand for the α2δ subunit of voltage-gated calcium channels. Mirogabalin is approved in Japan and several Asian countries for pain management.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, both male and female, after single oral dose administration.</p><h4>References</h4><ol><li><p>Yamamura, N, et al., &amp; Vashi, V (2021). Metabolism, excretion, and pharmacokinetics of [. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 51(5) 549–563. DOI:<a href=\"https://doi.org/10.1080/00498254.2021.1879408\">10.1080/00498254.2021.1879408</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33487061/\">https://pubmed.ncbi.nlm.nih.gov/33487061</a></p></li><li><p>Yamamura, N, et al., &amp; Nishiya, Y (2022). Pharmacokinetics and metabolism of mirogabalin, a novel α. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 52(1) 54–64. DOI:<a href=\"https://doi.org/10.1080/00498254.2022.2049396\">10.1080/00498254.2022.2049396</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35249464/\">https://pubmed.ncbi.nlm.nih.gov/35249464</a></p></li><li><p>Kato, M, et al., &amp; Ishizuka, H (2018). Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment. <i>Journal of clinical pharmacology</i> 58(1) 57–63. DOI:<a href=\"https://doi.org/10.1002/jcph.974\">10.1002/jcph.974</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28834546/\">https://pubmed.ncbi.nlm.nih.gov/28834546</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02BF03;
